About Avalo Therapeutics
Innovation driven by compassion.
- Industry
- Biotechnology
- Company size
- 11-50 employees
- Headquarters
- Chesterbrook, Pennsylvania
- Founded
- 2011
- Company type
- Public Company
Avalo Therapeutics is a clinical stage biotechnology company focused on the treatment of immune dysregulation. Avalo’s lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases.
For more information about Avalo, please visit www.avalotx.com.
Our highly targeted therapeutics have strong scientific and clinical rationale that enable accelerated clinical development and increased probability of success.
We are rapidly advancing a rich pipeline with broad clinical utility across Immunology, Immuno-oncology, and Rare Genetic Diseases.
Our focus is the development of innovative therapies in areas of high unmet need within the fields of Rare Pediatric and Orphan Diseases.
Specialties
- immunology
Company locations
1500 Liberty Ridge Dr, Chesterbrook, Pennsylvania 19087, US
540 Gaither Road, Suite 400, Rockville, Maryland 20850, US
Locations listed on the company profile. These may include offices outside the United States, and not every location is hiring.
Business areas
- Biotechnology
- Therapeutics
On LinkedIn
- Followers
- 6,166
- People linked to this company
- 48
People who list this company on LinkedIn, not a verified employee count. Figures reflect the saved company profile.
Funding raised
606,504,600 USD
Total reported by Crunchbase, in US dollars. This is funding raised, not company revenue or valuation.
Explore the company
Employer category
Other employer
Estimated from the company profile. This category has not been confirmed by the employer.